Genentech: Haochu Huang | Principal Scientist, Translational Oncology

Scientists / Our Scientists

"Genentech’s commitment to basic biology and innovation is fundamental to novel drug development."

Years at Genentech

Awards & Honors

I joined Genentech in 2016. Prior to Genentech, I was a faculty member at the University of Chicago studying immune tolerance and autoimmune disease. I was fascinated by tumor immunology as tumors represent a unique “self” to the immune system. The recent success of cancer immunotherapy has been revolutionizing the field, and I was thrilled to join Genentech to develop novel immunotherapies that could have direct impact on patients.

Featured Publication

Self-Antigen-Driven Thymic B Cell Class Switching Promotes T Cell Central Tolerance.

Cell Rep. 2016 Oct 4;17(2):387-398.

Perera J, Zheng Z, Li S, Gudjonson H, Kalinina O, Benichou JIC, Block KE, Louzoun Y, Yin D, Chong AS, Dinner AR, Weigert M, Huang H.

View Abstract

My lab focuses on evaluating the efficacy, pharmacokinetics, pharmacodynamics, mechanism of action, and combinatorial therapeutic strategies of small molecules and biologics against select targets in cancer immunotherapy. We utilize and develop various mouse models of tumor immunology. We work closely with our discovery colleagues in Cancer Immunology to inform preclinical target validation and molecule selection.

Joslin Diabetes Center, Harvard Medical School, Post-doctoral Fellow – 2007
Johns Hopkins University, Ph.D. in Developmental Biology – 2000
University of Science and Technology of China, B.S. in Biology – 1993

Damon Runyon Fellow – 2000-2003

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Haochu Huang

Principal Scientist, Translational Oncology

Featured Publication

Self-Antigen-Driven Thymic B Cell Class Switching Promotes T Cell Central Tolerance.